Thanks for sharing frohlir944. Nice to see Zenith get some attention.

There are many other players in the BET inhibitor field other than Zenith (ZEN-3694) and GSK (molebresib aka GSK525762) mentioned in the article. I compiled a list of BET inhibitor clinical trials about 1.5 years ago. It is outdated now and I don't know where many of these trials stand. But for castrate resistant prostate cancer there are at least 3 other players other than Zenith in the game: Gilead, GSK and Abbvie. The ones listed below for Gilead and GSK are active but not recruiting, whereas the Zenith trial is still listed as recruiting (despite completion date listed as June 2019).

Zenith: A Study of ZEN003694 in Combination With Enzalutamide in Patients With Metastatic Castration-Resistant Prostate Cancer

Gilead: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Participants With Metastatic Castrate-Resistant Prostate Cancer

GSK: Dose Escalation and Dose Expansion Study of GSK525762 in Combination With Androgen Deprivation Therapy and Other Agents in Subjects With Castrate-resistant Prostate Cancer

Abbvie: A Study Evaluating the Safety and Pharmacokinetics of ABBV-744 in Subjects With Advanced Prostate Cancer (CRPC) and Relapsed/Refractory Acute Myeloid Leukemia (AML) Cancer